World Journal of Gastrointestinal Oncology最新文献

{"title":"Pretreatment red blood cell distribution width as a predictive marker for postoperative complications after laparoscopic pancreatoduodenectomy.","authors":"Xian-Rang Cao, Yin-Long Xu, Jia-Wei Chai, Kai Zheng, Jun-Jie Kong, Jun Liu, Shun-Zhen Zheng","doi":"10.4251/wjgo.v17.i1.98168","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.98168","url":null,"abstract":"<p><strong>Background: </strong>Red blood cell distribution width (RDW) is associated with the development and progression of various diseases.</p><p><strong>Aim: </strong>To explore the association between pretreatment RDW and short-term outcomes after laparoscopic pancreatoduodenectomy (LPD).</p><p><strong>Methods: </strong>A total of 804 consecutive patients who underwent LPD at our hospital between March 2017 and November 2021 were retrospectively analyzed. Correlations between pretreatment RDW and clinicopathological characteristics and short-term outcomes were investigated.</p><p><strong>Results: </strong>Patients with higher pretreatment RDW were older, had higher Eastern Cooperative Oncology Group scores and were associated with poorer short-term outcomes than those with normal RDW. High pretreatment RDW was an independent risk factor for postoperative complications (POCs) (hazard ratio = 2.973, 95% confidence interval: 2.032-4.350, <i>P</i> < 0.001) and severe POCs of grade IIIa or higher (hazard ratio = 3.138, 95% confidence interval: 2.042-4.824, <i>P</i> < 0.001) based on the Clavien-Dino classification system. Subgroup analysis showed that high pretreatment RDW was an independent risk factor for Clavien-Dino classification grade IIIb or higher POCs, a comprehensive complication index score ≥ 26.2, severe postoperative pancreatic fistula, severe bile leakage and severe hemorrhage. High pretreatment RDW was positively associated with the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and was negatively associated with albumin and the prognostic nutritional index.</p><p><strong>Conclusion: </strong>Pretreatment RDW was a special parameter for patients who underwent LPD. It was associated with malnutrition, severe inflammatory status and poorer short-term outcomes. RDW could be a surrogate marker for nutritional and inflammatory status in identifying patients who were at high risk of developing POCs after LPD.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"98168"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dihydropyrimidine dehydrogenase polymorphisms in patients with gastrointestinal malignancies and their impact on fluoropyrimidine tolerability: Experience from a single Italian institution.","authors":"Mariarosaria D'Amato, Gennaro Iengo, Nicola Massa, Chiara Carlomagno","doi":"10.4251/wjgo.v17.i1.96822","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.96822","url":null,"abstract":"<p><strong>Background: </strong>Fluoropyrimidines are metabolized in the liver by the enzyme dihydropyrimidine dehydrogenase (DPD), encoded by the <i>DPYD</i> gene. About 7% of the European population is a carrier of <i>DPYD</i> gene polymorphisms associated with reduced DPD enzyme activity.</p><p><strong>Aim: </strong>To assess the prevalence of <i>DPYD</i> polymorphisms and their impact on fluoropyrimidine tolerability in Italian patients with gastrointestinal malignancies.</p><p><strong>Methods: </strong>A total of 300 consecutive patients with a diagnosis of gastrointestinal malignancy and treated with a fluoropyrimidine-based regimen were included in the analysis and divided into two cohorts: (1) 149 patients who started fluoropyrimidines after <i>DPYD</i> testing; and (2) 151 patients treated without <i>DPYD</i> testing. Among the patients in cohort A, 15% tested only the <i>DPYD2A</i> polymorphism, 19% tested four polymorphisms (<i>DPYD</i>2A, HapB3, c.2846A>T, and <i>DPYD</i>13), and 66% tested five polymorphisms including <i>DPYD</i>6.</p><p><strong>Results: </strong>Overall, 14.8% of patients were found to be carriers of a <i>DPYD</i> variant, the most common being <i>DPYD</i>6 (12.1%). Patients in cohort A reported ≥ G3 toxicities (<i>P</i> = 0.00098), particularly fewer nonhematological toxicities (<i>P</i> = 0.0028) compared with cohort B, whereas there was no statistically significant difference between the two cohorts in hematological toxicities (<i>P</i> = 0.6944). Significantly fewer chemotherapy dose reductions (<i>P</i> = 0.00002) were observed in cohort A compared to cohort B, whereas there was no statistically significant differences in chemotherapy delay.</p><p><strong>Conclusion: </strong>Although this study had a limited sample size, it provides additional information on the prevalence of <i>DPYD</i> polymorphisms in the Italian population and highlights the role of pharmacogenetic testing to prevent severe toxicity.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"96822"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BIBR1532 inhibits proliferation and metastasis of esophageal squamous cancer cells by inducing telomere dysregulation.","authors":"Qin Wang, Qing-Rong Li, Lei Xu, Zi-Chun Yuan, Xiao Liu, Mao-Ju Tang, Man Luo, Xiao-Wu Zhong, Qiang Ma, Xiao-Lan Guo","doi":"10.4251/wjgo.v17.i1.99376","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.99376","url":null,"abstract":"<p><strong>Background: </strong>Esophageal squamous cell carcinoma (ESCC) is a malignant tumor with high morbidity and mortality, and easy to develop resistance to chemotherapeutic agents. Telomeres are DNA-protein complexes located at the termini of chromosomes in eukaryotic cells, which are unreplaceable in maintaining the stability and integrity of genome. Telomerase, an RNA-dependent DNA polymerase, play vital role in telomere length maintain, targeting telomerase is a promising therapeutic strategy for cancer.</p><p><strong>Aim: </strong>To investigate the efficacy and underlying mechanisms of BIBR1532, a telomerase inhibitor, in ESCC.</p><p><strong>Methods: </strong>KYSE150 and KYSE410 cells were cultured and exposed to various concentrations of BIBR1532. Cell viability was assessed at 48 hours and 72 hours to determine the IC₅₀ values. The effects of BIBR1532 on ESCC cell proliferation, migration, and cellular senescence were evaluated using the cell counting kit-8 assay, plate colony formation assay, scratch assay, transwell assay, and β-galactosidase staining, respectively. Western blotting was performed to detect the expression of proteins in BIBR1532-treated ESCC cells, such as human telomerase reverse transcriptase (hTERT), key molecules involved in DNA damage response (DDR) or cellular senescence, as well as telomere-binding proteins. Additionally, a tumor-bearing nude mouse model was established to evaluate the anti-cancer effect of BIBR1532 <i>in vivo</i>.</p><p><strong>Results: </strong>The IC₅₀ values for KYSE150 and KYSE410 cells after 48 hours of BIBR1532 exposure were 48.53 μM and 39.59 μM, respectively. These values decreased to 37.22 μM and 22.71 μM, respectively, following a longer exposure of 72 hours. BIBR1532 exhibited dose-dependent effects on KYSE150 and KYSE410 cells, including decreased hTERT expression, inhibition of proliferation and metastasis, and induction of cellular senescence. Mechanistically, BIBR1532 upregulated the expression of the DDR protein, γ-H2AX, and activated the ataxia telangiectasia and Rad3-related protein (ATR)/ check point kinase 1 (CHK-1) and ataxia-telangiectasia mutated gene (ATM)/CHK2 pathways. BIBR1532 downregulated the expression of telomere-binding proteins, including telomeric-repeat binding factor 1 (TRF1), TRF2, protection of telomeres 1, and TIN2-interacting protein 1. In a nude mouse xenograft model, BIBR1532 significantly suppressed tumor growth, reduced hTERT expression, and increased γ-H2AX protein levels. Hematoxylin and eosin staining of various organs, including the heart, liver, spleen, lungs, and kidneys, revealed no apparent adverse effects.</p><p><strong>Conclusion: </strong>BIBR1532 exerts anti-cancer effects on ESCC by inducing DDR through the ATR/CHK1 and ATM/CHK2 pathways and downregulating the expression of telomere-binding proteins.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"99376"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete response of gallbladder cancer treated with gemcitabine and cisplatin chemotherapy combined with durvalumab: A case report and review of literature.","authors":"Kai Chen, Xu Feng, Yuan Shi, Xin-Lin Li, Zheng-Rong Shi, Xiang Lan","doi":"10.4251/wjgo.v17.i1.98433","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.98433","url":null,"abstract":"<p><strong>Background: </strong>Gallbladder cancer (GBC) is the most common and aggressive subtype of biliary tract cancer (BTC) and has a poor prognosis. A newly developed regimen of gemcitabine, cisplatin, and durvalumab shows promise for the treatment of advanced BTC. However, the efficacy of this treatment for GBC remains unclear.</p><p><strong>Case summary: </strong>In this report, we present a case in which the triple-drug regimen exhibited marked effectiveness in treating locally advanced GBC, thus leading to a long-term survival benefit. A 68-year-old man was diagnosed with locally advanced GBC, which rendered him ineligible for curative surgery. Following three cycles of therapy, a partial response was observed. After one year of combined therapy, a clinical complete response was successfully achieved. Subsequent maintenance therapy with durvalumab monotherapy resulted in a disease-free survival of 9 months for the patient. The patient experienced tolerable toxicities of reversible grade 2 nausea and fatigue. Tolerable adverse events were observed in the patient throughout the entirety of the treatment.</p><p><strong>Conclusion: </strong>The combination of gemcitabine and cisplatin chemotherapy with durvalumab was proven to be an effective treatment approach for advanced GBC, with manageable adverse events. Further research is warranted to substantiate the effectiveness of the combined regimen in the context of GBC.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"98433"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysregulation of genes involved in the long-chain fatty acid transport in pancreatic ductal adenocarcinoma.","authors":"Radu Cristian Poenaru, Elena Milanesi, Andrei Marian Niculae, Anastasia-Maria Dobre, Catalina Vladut, Mihai Ciocîrlan, Daniel Vasile Balaban, Vlad Herlea, Maria Dobre, Mihail Eugen Hinescu","doi":"10.4251/wjgo.v17.i1.98409","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.98409","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic ductal adenocarcinoma (PDAC) is an aggressive lethal malignancy with limited options for treatment and a 5-year survival rate of 11% in the United States. As for other types of tumors, such as colorectal cancer, aberrant <i>de novo</i> lipid synthesis and reprogrammed lipid metabolism have been suggested to be associated with PDAC development and progression.</p><p><strong>Aim: </strong>To identify the possible involvement of lipid metabolism in PDAC by analyzing in tumoral and non-tumoral tissues the expression level of the most relevant genes involved in the long-chain fatty acid (FA) import into cell.</p><p><strong>Methods: </strong>A gene expression analysis of <i>FASN</i>, <i>CD36</i>, <i>SLC27A1</i>, <i>SLC27A2</i>, <i>SLC27A3</i>, <i>SLC27A4</i>, <i>SLC27A5</i>, <i>ACSL1</i>, and <i>ACSL3</i> was performed by qRT-PCR in 24 tumoral PDAC tissues and 11 samples from non-tumoral pancreatic tissues obtained <i>via</i> fine needle aspiration or <i>via</i> surgical resection. The genes were considered significantly dysregulated between the groups when the p value was < 0.05 and the fold change (FC) was ≤ 0.5 and ≥ 2.</p><p><strong>Results: </strong>We found that three FA transporters and two long-chain acyl-CoA synthetases genes were significantly upregulated in the PDAC tissue compared to the non-tumoral tissue: <i>SLC27A2</i> (FC = 5.66; <i>P</i> = 0.033), <i>SLC27A3</i> (FC = 2.68; <i>P</i> = 0.040), <i>SLC27A4</i> (FC = 3.13; <i>P</i> = 0.033), <i>ACSL1</i> (FC = 4.10; <i>P</i> < 0.001), and <i>ACSL3</i> (FC = 2.67; <i>P</i> = 0.012). We further investigated any possible association between the levels of the analyzed mRNAs and the specific characteristics of the tumors, including the anatomic location, the lymph node involvement, and the presence of metastasis. A significant difference in the expression of <i>SLC27A3</i> (FC = 3.28; <i>P</i> = 0.040) was found comparing patients with and without lymph nodes involvement with an overexpression of this transcript in 17 patients presenting tumoral cells in the lymph nodes.</p><p><strong>Conclusion: </strong>Despite the low number of patients analyzed, these preliminary results seem to be promising. Addressing lipid metabolism through a broad strategy could be a beneficial way to treat this malignancy. Future <i>in vitro</i> and <i>in vivo</i> studies on these genes may offer important insights into the mechanisms linking PDAC with the long-chain FA import pathway.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"98409"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curcumin in gastric cancer treatment: A commentary on mechanistic insights and future directions.","authors":"Xin-Yue Wei, Wen-Bo Cao, Sai-Jun Mo, Zhi-Yan Sun","doi":"10.4251/wjgo.v17.i1.100369","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.100369","url":null,"abstract":"<p><p>The study by Yang <i>et al</i> presents a comprehensive investigation into the therapeutic potential of curcumin for gastric cancer (GC). Using network pharmacology, the researchers identified 48 curcumin-related genes, 31 of which overlap with GC targets. Key genes, including <i>ESR1</i>, <i>EGFR</i>, <i>CYP3A4</i>, <i>MAPK14</i>, <i>CYP1A2</i>, and <i>CYP2B6</i>, are linked to poor survival in GC patients. Molecular docking confirmed strong binding affinity of curcumin to these genes. <i>In vitro</i> experiments demonstrated that curcumin effectively inhibits the growth and proliferation of <i>BGC-823</i>, suggesting its therapeutic potential in GC through multiple targets and pathways.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"100369"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coagulation indices and fibrinogen degradation products as predictive biomarkers for tumor-node-metastasis staging and metastasis in gastric cancer.","authors":"Yi-Qing Shen, Qiu-Wan Wei, Yi-Ren Tian, Yun-Zhi Ling, Min Zhang","doi":"10.4251/wjgo.v17.i1.98725","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.98725","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is a prevalent malignancy with a substantial health burden and high mortality rate, despite advances in prevention, early detection, and treatment. Compared with the global average, Asia, notably China, reports disproportionately high GC incidences. The disease often progresses asymptomatically in the early stages, leading to delayed diagnosis and compromised outcomes. Thus, it is crucial to identify early diagnostic biomarkers and enhance treatment strategies to improve patient outcomes and reduce mortality.</p><p><strong>Aim: </strong>To investigate coagulation and fibrinogen products in GC tumor-node-metastasis (TNM) stage and metastasis correlation.</p><p><strong>Methods: </strong>Retrospectively analyzed the clinical data of 148 patients with GC treated at the Civil Aviation Shanghai Hospital between December 2022 and December 2023. The associations of coagulation indices - partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), fibrinogen, fibrinogen degradation products (FDP), fasting blood glucose, and D-dimer (D-D) with TNM stage and distant metastasis were examined.</p><p><strong>Results: </strong>Prolongation of APTT, PT, and TT was significantly correlated with the GC TNM stage. Hence, abnormal coagulation system activation was closely related to disease progression. Elevated FDP and D-D were significantly associated with distant metastasis in GC (<i>P</i> < 0.05), suggesting that increased fibrinolytic activity contributes to increased metastatic risk.</p><p><strong>Conclusion: </strong>Our Results reveal coagulation indices, FDPs as GC biomarkers, reflecting abnormal coagulation/fibrinolysis, aiding disease progression, metastasis prediction, and helping clinicians assess thrombotic risk for early intervention and personalized treatment plans.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"98725"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between autoimmune gastritis and gastric polyps: Clinical characteristics and risk factors.","authors":"Jing-Zheng Jin, Xiao Liang, Shu-Peng Liu, Rui-Lan Wang, Qing-Wei Zhang, Yu-Feng Shen, Xiao-Bo Li","doi":"10.4251/wjgo.v17.i1.92908","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.92908","url":null,"abstract":"<p><strong>Background: </strong>The relationship between autoimmune gastritis (AIG) and gastric polyps (GPs) is not well understood.</p><p><strong>Aim: </strong>To explore the clinical characteristics and risk factors of AIG with GPs in patients.</p><p><strong>Methods: </strong>This double center retrospective study included 530 patients diagnosed with AIG from July 2019 to July 2023. We collected clinical, biochemical, serological, and demographic data were of each patient. Logistic regression analyses, both multivariate and univariate, were conducted to pinpoint independent risk factors for GPs in patients with AIG patients. Receiver operating characteristic curves were utilized to establish the optimal cutoff values, sensitivity, and specificity of these risk factors for predicting GPs in patients with AIG.</p><p><strong>Results: </strong>Patients with GPs had a higher median age than those without GPs [61 (52.25-69) years <i>vs</i> 58 (47-66) years, <i>P</i> = 0.006]. The gastrin-17 levels were significantly elevated in patients with GPs compared with those without GPs [91.9 (34.2-138.9) pmol/mL <i>vs</i> 60.9 (12.6-98.4) pmol/mL, <i>P</i> < 0.001]. Additionally, the positive rate of parietal cell antibody (PCA) antibody was higher in these patients than in those without GPs (88.6% <i>vs</i> 73.6%, <i>P</i> < 0.001). Multivariate and univariate analyses revealed that PCA positivity [odds ratio (OR) = 2.003, <i>P</i> = 0.017], pepsinogen II (OR = 1.053, <i>P</i> = 0.015), and enterochromaffin like cells hyperplasia (OR = 3.116, <i>P</i> < 0.001) were significant risk factors for GPs, while pepsinogen I was identified as a protective factor.</p><p><strong>Conclusion: </strong>PCA positivity and enterochromaffin like cells hyperplasia are significant risk factor for the development of GPs in patients with AIG. Elevated gastrin-17 levels may also play a role in this process. These findings suggest potential targets for further research and therapeutic intervention in managing GPs in patients with AIG.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"92908"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143011735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gallbladder carcinoma in the era of artificial intelligence: Early diagnosis for better treatment.","authors":"Ismail As Burud, Sherreen Elhariri, Nabil Eid","doi":"10.4251/wjgo.v17.i1.99994","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.99994","url":null,"abstract":"<p><p>Gallbladder carcinoma (GBC) is the most common malignant tumor of biliary tract, with poor prognosis due to its aggressive nature and limited therapeutic options. Early detection of GBC is a major challenge, with most GBCs being detected accidentally during cholecystectomy procedures for gallbladder stones. This letter comments on the recent article by Deqing <i>et al</i> in the <i>World Journal of Gastrointestinal Oncology</i>, which summarized the various current methods used in early diagnosis of GBC, including endoscopic ultrasound (EUS) examination of the gallbladder for high-risk GBC patients, and the use of EUS-guided elastography, contrast-enhanced EUS, trans-papillary biopsy, natural orifice transluminal endoscopic surgery, magnifying endoscopy, choledochoscopy, and confocal laser endomicroscopy when necessary for early diagnosis of GBC. However, there is a need for novel methods for early GBC diagnosis, such as the use of artificial intelligence and non-coding RNA biomarkers for improved screening protocols. Additionally, the use of <i>in vitro</i> and animal models may provide critical insights for advancing early detection and treatment strategies of this aggressive tumor.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"99994"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the landscape of pediatric pancreatic tumors: Insights from Japan.","authors":"Savvas Lampridis","doi":"10.4251/wjgo.v17.i1.101477","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.101477","url":null,"abstract":"<p><p>Pediatric pancreatic tumors, though rare, pose significant diagnostic and management challenges. The recent, 22-year nationwide survey on pediatric pancreatic tumors in Japan by Makita <i>et al</i> offers valuable insights into this uncommon entity, revealing striking geographical variations and questioning current treatment paradigms. This editorial commentary analyzes the study's key findings, including the predominance of solid pseudopapillary neoplasms and their younger age of onset, which contrast sharply with Western data. It explores the implications for clinical practice and research, emphasizing the need for population-specific approaches to diagnosis and treatment. The revealed limited institutional experience and surgical management patterns prompt a reevaluation of optimal care delivery for these complex cases, suggesting benefits of centralizing healthcare services. Furthermore, the commentary advocates for international collaborative studies to elucidate the genetic, environmental, and lifestyle factors influencing the development and progression of pediatric pancreatic tumors across diverse populations. It also outlines future directions, calling for advancements in precision medicine and innovative care delivery models to improve global patient outcomes. Unraveling Makita <i>et al</i>'s findings within the broader landscape of pediatric oncology can stimulate further research and clinical advancements in managing pancreatic and other rare tumors in children.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"101477"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}